KOL

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Retrieved on: 
Monday, March 25, 2024
ALS, Disease, KOL, University, Anterior grey column, Therapy, DSM-IV codes, Division, Medical laboratory, Pathology, Pharmaceutical industry

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET.

Key Points: 
  • MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET.
  • The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome considerations for the upcoming topline data read-out for the Phase 1b/2a trial expected in the second quarter of 2024.
  • To access the conference call, please register using the audio conference link here .
  • A webcast replay of the event will be available on the Events page of Avenue’s website at https://avenuetx.com/ .

VML and Definitive Healthcare announce partnership to transform key opinion leader management

Retrieved on: 
Friday, March 22, 2024
CRM, Partnership, Health, KOL, VML, Definitive, Sales

and LONDON, March 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ) and VML Health announced a first-of-its-kind partnership that gives clients the ability to manage their entire key opinion leader (KOL) identification and engagement operation from an integrated solution.

Key Points: 
  • and LONDON, March 22, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH ) and VML Health announced a first-of-its-kind partnership that gives clients the ability to manage their entire key opinion leader (KOL) identification and engagement operation from an integrated solution.
  • This partnership provides an answer to the increasingly complex challenges that the health industry faces when identifying and engaging with the most relevant KOLs at a global level.
  • The new solution has been created by linking VML Health’s digital KOL engagement platform and Definitive Healthcare’s comprehensive global KOL data available through the Monocl ExpertInsight platform.
  • "This will transform the way pharmaceutical companies interact with healthcare professionals,” says Claire Gillis, CEO of VML Health.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
Thursday, March 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

Oracle AI Announces Successful Launch on MEXC Exchange, Revolutionizing Cryptocurrency Trading with Advanced AI Insights

Retrieved on: 
Wednesday, March 20, 2024
USDT, AI alignment, Artificial intelligence, KOL, Noise, Cryptocurrency

Oracle AI , the pioneering technology project redefining cryptocurrency trading through artificial intelligence, announces its recent successful launch on the MEXC Exchange.

Key Points: 
  • Oracle AI , the pioneering technology project redefining cryptocurrency trading through artificial intelligence, announces its recent successful launch on the MEXC Exchange.
  • In a significant development for the cryptocurrency trading community, Oracle AI has officially marked its entry into the market with a resounding launch on the MEXC Exchange.
  • Oracle AI is at the forefront of leveraging AI to sift through the noise in the cryptocurrency market, providing investors with a clear advantage.
  • "The launch of $ORACLE on the MEXC Exchange not only signifies a milestone for our team but also represents a pivotal moment for the cryptocurrency community," said Nick, the lead developer at Oracle AI.

TFF Pharmaceuticals Announces Update on Clinical Programs

Retrieved on: 
Wednesday, March 20, 2024
Health, TFF, P-value, Acceleration, Partnership, Patient, IPA, EAP, KOL, Mortality, Clinical research associate, Microsoft Access, Calendar, Potential, Safety, Voriconazole, Pharmaceutical industry

FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, is announcing data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of TFF TAC, the potential to address a significant unmet need in lung transplant medicine, and substantial market opportunity, the Company has made the decision to prioritize the TFF TAC program and focus resources on the acceleration of its clinical pathway towards registration.

Key Points: 
  • “However, after a rigorous assessment of our pipeline, including the significant capital and resources required to progress both clinical development programs, we will focus our clinical development efforts and financial resources on TFF TAC.
  • In summary, for TFF TAC, eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC in the Phase 2 study.
  • TFF TAC continues to demonstrate favorable safety results with no mortality or discontinuations due to adverse events.
  • The Company will host a conference call on Wednesday, March 27, 2024, at 4:30 PM Eastern Time, to discuss updated clinical data for the TFF TAC and TFF VORI.

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Retrieved on: 
Wednesday, March 20, 2024
NCP, BID, Patient, KOL, IND, DED, Safety, Pain, Telecanthus, FDA, Health, Pharmaceutical industry

The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth.

Key Points: 
  • The company will also host a Key Opinion Leader (KOL) event to discuss the findings in depth.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The KOL call will feature prominent experts in the field of dry eye disease.
  • “The upcoming data release follows the successful completion of OKYO Pharma's Phase 2 trial, which focused on assessing the efficacy and safety of OK-101, our novel topical therapeutic candidate for dry eye disease,” said Gary S. Jacob, Ph.D., CEO of OKYO Pharma.

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Retrieved on: 
Tuesday, March 19, 2024
HER2, Acute leukemia, Exercise, Index, Exchange, Colorectal cancer, MMR, Memorial, Headache, Patient, Research, Diarrhea, Brain, CML, KOL, Aes, Sale, Cancer, Security (finance), IND, MBA, Prospectus, MBC, Nausea, Therapy, CRC, PIPE, Pharmacokinetics, MTD, Food, Pharmaceutical industry

BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.

Key Points: 
  • “The additional funding further strengthens our balance sheet and enables us to achieve critical, longer-term clinical milestones as we advance our parallel lead programs, ELVN-001 and ELVN-002.
  • Enliven anticipates the gross proceeds from the private placement to be approximately $90 million, before deducting offering expenses.
  • The PIPE financing is expected to close on or about March 21, 2024, subject to satisfaction of customary closing conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Retrieved on: 
Tuesday, March 19, 2024
Retina, University of Nevada, Reno, Houston Methodist Hospital, Webcast, Associate, ASX, KOL, University, Doctor of Philosophy, MBA, University of Illinois Urbana-Champaign, Shore, AMD, FACS, Medicine, Pharmaceutical industry

Additionally, Opthea will provide a strategic outlook.

Key Points: 
  • Additionally, Opthea will provide a strategic outlook.
  • A live question and answer session will follow the formal presentations.
  • To register for this live webcast, click here .
  • A replay of the webcast will be made available on the Company’s website.